Opicapone Reduces Off-Time by 2 Hours in Parkinson’s Disease Patients as Add-On to Levodopa: Ono

Ono Pharmaceutical announced on March 19 the results of a PIII clinical trial of the novel catechol-O-methyltransferase (COMT) inhibitor opicapone for the treatment of Parkinson’s disease (PD), which Ono has exclusive rights to develop and commercialize in Japan. The trial...read more